bupivacaine
Commercial- Indications
- Local anesthesia
Company intelligence / Profile preview
Zhejiang Boxiao Bio-Pharmaceutical is developing a pipeline including a novel biologic, Teprotumumab (bx-biopharm), which is in Phase 1 for Graves Ophthalmopathy, and an advanced generic, Bupivacaine liposome injection, which is in preclinical/bioequivalence studies for pain management. The company also has commercialized generic products such as Epinephrine bitartrate and Norepinephrine bitartrate, and supplies voclosporin intermediates.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zhejiang Boxiao Bio-Pharmaceutical.